PT  - JOURNAL ARTICLE
AU  - Tianyu Tang
AU  - Xing Huang
AU  - Gang Zhang
AU  - Tingbo Liang
TI  - Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
AID  - 10.1136/jitc-2022-005065
DP  - 2022 Jul 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e005065
VI  - 10
IP  - 7
4099  - http://jitc.bmj.com/content/10/7/e005065.short
4100  - http://jitc.bmj.com/content/10/7/e005065.full
SO  - J Immunother Cancer2022 Jul 01; 10
AB  - Oncolytic peptides are highly effective on remodeling the tumor microenvironment and potentiating the anticancer immunity through multiple mechanisms, particularly by inducing immunogenic cell death. Intriguingly, a recent study demonstrates that LTX-315, one of the most promising and extensively studied oncolytic peptides, inhibits PD-L1 expression via ATP11B, thus enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. Therefore, this commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, further highlighting the potential issues and directions of oncolytic peptides in cancer immunotherapy.